Specialty enzymes market seen doubling by 2035

The global specialty enzymes market is projected to rise from $7.68 billion in 2026 to $16.32 billion by 2035, according to Market Research Future. Growth is being driven by pharmaceutical biocatalysis, AI-guided enzyme engineering and regulatory pressure for greener industrial chemistry.

Why it matters: - Specialty enzymes are moving from a niche input to a core tool for drug manufacturing, food processing and green chemistry. - The market’s growth reflects structural demand, not a short-term spending cycle. - Enzyme adoption can reduce hazardous waste, lower total process costs and help manufacturers meet carbon and disclosure rules.

What happened: - Market Research Future said the global specialty enzymes market will grow from $7.68 billion in 2026 to $16.32 billion by 2035. - The forecast implies an 8.75% CAGR during 2026-2035. - The market base was estimated at $7.06 billion in 2025. - A sample report is available here. - The full report is available here.

The details: - Pharmaceutical biocatalysis is a major driver, with global drugmakers expected to spend $3.8 billion on enzyme-mediated chiral synthesis in 2024, up from $2.6 billion in 2021. - More than 40 new drug applications have referenced enzymatic processes in chemistry-manufacturing-controls sections after the FDA’s 2023 guidance on biocatalytic production pathways for small-molecule APIs. - The FDA’s 2023 expansion of enzyme-based therapeutic approvals opened a $1.4 billion addressable pipeline. - AI-guided protein engineering has cut enzyme development cycles from about 4.5 years to 8-14 months, based on a 2024 Nature Biotechnology analysis. - Startups using generative protein models raised $1.2 billion in Series B and C funding across 2023-2024. - Investments in computational enzyme design exceeded $2.1 billion globally in 2024. - Cloud-based protein-structure databases now catalog more than 200 million predicted enzyme folds. - By 2030, generative AI models are expected to produce more than 10,000 novel enzyme candidates annually, versus fewer than 500 from conventional directed evolution in 2024. - The European Green Deal requires 30% of industrial chemical processes to shift to bio-based alternatives by 2030. - The report says enzymatic processes can be 15%-30% cheaper on a total-cost-of-ownership basis than conventional chemistry alternatives. - Enzyme cocktails for mixed plastic waste and agricultural residues represent a $2.3 billion addressable opportunity by 2030, according to the Ellen MacArthur Foundation’s circular-economy enzyme roadmap. - Mandatory ESG disclosure rules, including the EU’s Corporate Sustainability Reporting Directive and the SEC’s climate-risk rules, are increasing pressure to document lower hazardous catalyst use.

Between the lines: - The forecast points to a market being shaped by regulation as much as by end-user demand. - AI is changing the economics of enzyme discovery, which could shift value away from traditional fermentation-heavy models and toward design-led firms. - Regional policy is reinforcing demand, especially in the U.S., Europe and Asia-Pacific, where pharma, diagnostics and industrial bio-manufacturing incentives are strongest. - The report describes a moderately competitive market, with the top five players holding an estimated 45%-52% combined share and the HHI in the 900-1,200 range. - Novonesis is described as the market leader, with about 14%-18% of global revenue. - IFF received EFSA approval in April 2024 for a carbohydrase blend for resistant-starch modification in bakery products. - DSM-Firmenich completed its merger in May 2023 and is focused on precision fermentation and advanced enzyme systems.

What’s next: - The report expects AI-driven enzyme design to become a central operating model for biocatalysis by 2030. - Companies that monetize enzyme datasets through licensing and co-development could capture a larger share of market value by 2032. - The report says this shift could redistribute 15%-20% of specialty enzymes revenue toward pure-play enzyme design firms. - Demand should stay strong across pharmaceuticals, food and beverages, and industrial bio-processing as governments continue to push cleaner manufacturing.

The bottom line: - Specialty enzymes are set to become a bigger, more strategic part of global manufacturing as AI, regulation and pharma adoption converge.